Secondary Lymphedema
15
1
2
8
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
6.7%
1 terminated out of 15 trials
88.9%
+2.3% vs benchmark
0%
0 trials in Phase 3/4
25%
2 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 8 completed trials
Clinical Trials (15)
Scapulothoracic Stabilization and Postural Training in Upper Extremity Lymphedema
Study to Evaluate the Safety and Effectiveness of Dayspring for Lower Extremity Lymphedema
Imaging Biomarkers of Lymphatic Dysfunction
Clinical Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema (AdeLE)
Late Side-effects After Cervical Cancer Treatment - Prevention and Treatment
Lymphaticovenous Anastomosis as Treatment for Lymphedema
A Phase I Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema
Supermicrosurgery for Breast Cancer Survivors With Lymphedema.
Complete Decongestive Therapy on Head and Neck Lymphedema
Proof-of-concept Study of LymphMonitor 1.0 to Assess the Lymphatic Vessel Function
Complete Decongestive Therapy With Negative Pressure for Lipedema and Lymphedema Therapy
Feasibility of Lymph Edema-induced Reticulation Subtraction Based on Computerized Tomography
Lymphatic Function in Patients Who Have Undergone Breast Cancer Treatment
Hyperbaric Oxygen Therapy to Reduce Lymphedema After Breast Cancer -an Explorative Clinical Trial
Physical Therapies in the Decongestive Treatment of Lymphedema